



Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 to Be Presented at the 32nd Annual San Antonio Breast Cancer Symposium

December 3, 2009 9:02 PM EST

SOUTH SAN FRANCISCO, CA, Dec 03, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing non-clinical data relating to GSK-923295, an inhibitor of centromere-associated protein E (CENP-E), is scheduled to be presented as a poster presentation at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS) to be held December 9-13, 2009 at the Henry B. Gonzalez Convention Center, San Antonio, Texas. GSK-923295 is currently being studied in a GlaxoSmithKline sponsored Phase I, first time in humans clinical trial designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetic profile of this novel drug candidate in patients with advanced, refractory solid tumors.

Poster Presentation at SABCS

Abstract #2020: "A Systems Analysis of Mitotic Apparatus Inhibitors Defines a Response Network for Breast Cancer" is scheduled to be displayed as a poster presentation on Friday, December 11, 2009 in Poster Session 2. The presentation will be made by Zhi Hu, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA from 7:00 AM - 9:00 AM Central Time in Exhibit A-B in the Henry B. Gonzalez Convention Center.

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil (formerly CK-1827452), is in Phase II clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing CK-2017357, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. CK-2017357 is in Phase I clinical development. Cytokinetics is also conducting non-clinical development of compounds that inhibit smooth muscle contractility and which may be useful as potential treatments for diseases and conditions such as systemic hypertension, pulmonary arterial hypertension or bronchoconstriction. In addition, prior Cytokinetics' research generated three anti-cancer drug candidates in Phase I clinical development: ispinesib, SB-743921 and GSK-923295. Cytokinetics is seeking a partner for ispinesib and SB-743921. GSK-923295 is being developed by GlaxoSmithKline in collaboration with Cytokinetics. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations and the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

Contacts: [

Cytokinetics, Incorporated

Christopher S. Keenan (Investors and Media)

Director, Investor Relations

(650) 624-3000

SOURCE: Cytokinetics, Inc.